NEW YORK--(BUSINESS WIRE)--
Kirby McInerney LLP is investigating potential claims against the Board of Directors of NuPathe Inc. (“NuPathe” or the “Company”) (PATH) concerning the proposed acquisition of the Company by Endo Health Solutions Inc. (“Endo”) (ENDP). Under the terms of the definitive merger agreement, NuPathe stockholders will receive $2.85 in cash for each share of NuPathe owned, valuing the transaction at approximately $105 million.
The investigation concerns whether the NuPathe Board of Directors violated its fiduciary duties by agreeing to the proposed transaction and whether the $2.85 per share proposed consideration adequately values NuPathe’s common stock.
If you are a NuPathe stockholder and wish to obtain additional information, please contact J. Brandon Walker, Esq. by email at firstname.lastname@example.org, by telephone at (212) 699-1145 or (888) 529-4787, or by filling out this contact form. There is no cost or obligation to you.
Kirby McInerney LLP is a New York-based law firm concentrating in securities, shareholder, whistleblower, antitrust and consumer litigation. For additional information, please go to www.kmllp.com.
- Investment & Company Information
J. Brandon Walker, Esq., 212-699-1145 / 888-529-4787